二甲双胍对子宫内膜癌的影响:系统综述与Meta分析
该系统综述与Meta分析于2017年1月检索多个数据库及灰色文献,纳入19项研究,评估二甲双胍对非典型子宫内膜增生和子宫内膜癌患者的作用。结果显示二甲双胍与非典型子宫内膜增生逆转为正常子宫内膜及细胞增殖标志物染色降低相关,使用者总生存期较高,但研究间异质性高,需进一步前瞻性对照试验。
要点
- 二甲双胍与非典型子宫内膜增生逆转为正常子宫内膜相关。
- 二甲双胍与细胞增殖标志物染色从51.94%降至34.47%相关,但研究间异质性高。
- 二甲双胍使用者子宫内膜癌患者总生存期较高(HR=0.82),需进一步前瞻性试验。
核心结论
- 尽管分析的研究异质性高,本综述提示辅助二甲双胍治疗可能有助于非典型子宫内膜增生逆转为正常子宫内膜组织学、减少与肿瘤进展相关的细胞增殖标志物、并改善子宫内膜癌的总生存期。
- 需要进一步开展旨在探讨辅助二甲双胍对临床结局影响的前瞻性对照试验才能得出明确结论。
研究设计与样本
- 系统综述与Meta分析,于2017年1月检索Cochrane、LILACS、PubMed、Scopus和Web of Science,并通过Google SCHOLAR、ProQuest和Open Grey进行灰色文献检索。
- 共纳入19项研究,包含二甲双胍使用者与非使用者相比的非典型子宫内膜增生逆转、细胞增殖标志物表达和总生存期信息。
主要发现
- 二甲双胍与非典型子宫内膜增生逆转为正常子宫内膜相关。
- 二甲双胍与细胞增殖标志物染色降低相关,从51.94%(CI=36.23%至67.46%)降至34.47%(CI=18.55%至52.43%)。
- 研究间存在高异质性。
- 二甲双胍使用者子宫内膜癌患者的总生存期高于非二甲双胍使用者和非糖尿病患者(HR=0.82;CI:0.70-0.95;p=0.09,I2=40%)。
关键数值与推荐
- 细胞增殖标志物染色从51.94%(CI=36.23%至67.46%)降至34.47%(CI=18.55%至52.43%)。
- 二甲双胍使用者子宫内膜癌患者总生存期HR=0.82(CI:0.70-0.95;p=0.09,I2=40%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究间存在高异质性。
- 需要进一步开展旨在探讨辅助二甲双胍对临床结局影响的前瞻性对照试验才能得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endometrial cancer is one of the most common gynecological cancers, which is frequently preceded by atypical endometrial hyperplasia, a premalignant lesion. Metformin, an antidiabetic drug, has emerged as a new adjunctive strategy for different cancer types, including endometrial cancer. This systematic review and meta-analysis aimed to evaluate the effects of metformin in atypical endometrial hyperplasia and endometrial cancer patients. METHODS: The search was conducted on January 2017 and the articles were collected in Cochrane, LILACS, PubMed, Scopus and Web of Science. A grey literature search was undertaken using Google SCHOLAR, ProQuest and Open Grey. Nineteen studies were included, which contained information about the following outcomes: reversal of atypical endometrial hyperplasia, cellular proliferation biomarkers expression and overall survival in metformin-users compared to non-users. RESULTS: Metformin was associated with reversion of atypical endometrial hyperplasia to a normal endometrial, and with decreased cell proliferation biomarkers staining, from 51.94% (CI=36.23% to 67.46%) to 34.47% (CI=18.55% to 52.43%). However, there is a high heterogeneity among studies. Metformin-users endometrial cancer patients had a higher overall survival compared to non-metformin users and non-diabetic patients (HR=0.82; CI: 0.70-0.95; p=0.09, I2=40%). CONCLUSION: Regardless the high heterogeneity of the analyzed studies, the present review suggests that adjunct metformin treatment may assist in the reversal of atypical endometrial hyperplasia to normal endometrial histology, in the reduction of cell proliferation biomarkers implicated in tumor progression, and in the improvement of overall survival in endometrial cancer. Further work on prospective controlled trials designed to address the effects of adjunct metformin on clinical outcomes is necessary for definite conclusions.
引用
- Meireles CG, Pereira SA, Valadares LP, et al. Effects of metformin on endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol. 2017. PMID: 28760367. doi:10.1016/j.ygyno.2017.07.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。